Whalesbook
Aurobindo Pharma's CFO, S Subramanian, shared insights into the company's strategic initiatives. The company is working towards achieving break-even for its loss-making China facility by Q3-Q4 FY26, supported by capacity ramp-up and product approvals. Domestic operations are improving Pen-G production, with a request for Minimum Import Price. Growth drivers include US facility commercialization, biosimilars, and contract manufacturing, aiming for 20-21% margins by FY26.